On this day, we stand together—not only with our collaborators in Regensburg, Erlangen, Würzburg, and beyond—but also with cancer research institutions across Europe and around the world. Together, we share knowledge, commitment, and a common goal: improving outcomes for patients.

At CRC/TRR 221, our mission closely aligns with this year’s focus. We are dedicated to advancing innovative immune modulation strategies to enhance the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) in leukemia treatment.

Our research aims to prevent graft-versus-host disease (GvHD)—a serious complication in which donor immune cells attack the patient’s body—while preserving the beneficial graft-versus-leukemia (GvL) effect, where these cells eliminate remaining leukemia cells.

“Every scientific breakthrough we pursue is driven by one priority: improving the lives of patients. Our goal is to deliver not only longer survival, but better quality of life for every individual affected by leukemia.”, as Professor Wolfgang Herr emphasizes.

Ultimately, our objective is to enhance the safety and efficacy of stem cell transplants, extend life expectancy, and improve patients’ quality of life following treatment.

Together with our clinical partners at UK-Regensburg, UK-Würtzburg, UK-Erlangen and across our network, we continue to place patients at the heart of everything we do.

Our collaborative efforts are driving meaningful change in leukemia treatment.